Armistice Capital »

Cytokinetics shares owned by Armistice Capital

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Armistice Capital

Quarter filed Position value Share count Share price at filing
2024-03-31 $156M 2.2M 70.11

More positions owned by Armistice Capital

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Ptc Therapeutics I (PTCT)
Cytokinetics Com New (CYTK)
Neurocrine Biosciences (NBIX)
Incyte Corporation (INCY)
Supernus Pharmaceuticals (SUPN)
Argenx Se Sponsored Adr (ARGX)
Deciphera Pharmaceuticals (DCPH)
Agios Pharmaceuticals (AGIO)
Immunovant (IMVT)
Sanofi Sponsored Adr (SNY)
Aurinia Pharmaceuticals (AUPH)
Dentsply Sirona (XRAY)
Travere Therapeutics (TVTX)

View all positions for Armistice Capital

Top funds holding Cytokinetics

BlackRock
FMR
Vanguard Group
Wellington Management Company
Bank of America Corporation
T. Rowe Price Investment Management
T. Rowe Price Associates
Marshall Wace
Pentwater Capital Management
Geode Capital Management
Armistice Capital
HAP Trading
Susquehanna International
Boxer Capital
Melqart Asset Management

View all funds holding Cytokinetics